Edition:
United States

Dova Pharmaceuticals Inc (DOVA.OQ)

DOVA.OQ on NASDAQ Stock Exchange Global Market

32.31USD
23 Feb 2018
Change (% chg)

$-0.47 (-1.43%)
Prev Close
$32.78
Open
$33.00
Day's High
$33.36
Day's Low
$31.09
Volume
539,217
Avg. Vol
39,155
52-wk High
$35.52
52-wk Low
$16.98

Latest Key Developments (Source: Significant Developments)

Dova Pharmaceuticals Says Public Offering Of 2.50 Mln Shares Priced At $32 per Share
Thursday, 22 Feb 2018 07:30pm EST 

Feb 22 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS, INC. ANNOUNCES PRICING OF OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 2.50 MILLION COMMON SHARES PRICED AT $32.00 PER SHARE.  Full Article

Dova Pharma Files For Offering Of Up To 2.5 Mln Shares
Tuesday, 20 Feb 2018 04:27pm EST 

Feb 20 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO 2.5 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING.  Full Article

Dova Pharmaceuticals Announces Proposed Offering Of Common Stock
Tuesday, 20 Feb 2018 04:05pm EST 

Feb 20 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS, INC. ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.SAYS OFFERING 2.50 MILLION COMMON SHARES.  Full Article

Dova Pharmaceuticals Reports Qtrly Loss Per Share $‍0.36​
Thursday, 15 Feb 2018 04:05pm EST 

Feb 15 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING AND FINANCIAL RESULTS.DOVA PHARMACEUTICALS INC QTRLY LOSS PER SHARE $‍0.36​.  Full Article

Dova Pharmaceuticals Announces FDA Acceptance Of The Avatrombopag New Drug Application With Priority Review
Monday, 27 Nov 2017 04:05pm EST 

Nov 27 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF THE AVATROMBOPAG NEW DRUG APPLICATION (NDA) WITH PRIORITY REVIEW.DOVA PHARMACEUTICALS INC - PDUFA GOAL DATE FOR AN FDA DECISION IS MAY 21, 2018 FOR NDA​.  Full Article

Dova Pharmaceuticals reports third quarter results
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - Dova Pharmaceuticals Inc :Dova Pharmaceuticals reports third quarter 2017 operating and financial results.Dova Pharmaceuticals Inc - qtrly ‍net loss per share, basic and diluted $0.38​.  Full Article

Dova Pharmaceuticals announces New Drug Application submission to FDA
Friday, 22 Sep 2017 07:00am EDT 

Sept 22 (Reuters) - Dova Pharmaceuticals Inc :Dova Pharmaceuticals announces New Drug Application submission to FDA for avatrombopag, a second generation thrombopoietin receptor agonist.Dova Pharmaceuticals Inc - ‍in both trials, avatrombopag met primary and secondary efficacy endpoints with high statistical significance​.Dova pharmaceuticals inc - ‍submission of a New Drug Application to U.S. Food and Drug Administration for avatrombopag​.  Full Article

Dova Pharmaceuticals qtrly net loss per share, basic and diluted $0.32
Thursday, 10 Aug 2017 04:05pm EDT 

Aug 10 (Reuters) - Dova Pharmaceuticals Inc :Dova Pharmaceuticals reports second quarter 2017 operating and financial results.Qtrly net loss per share, basic and diluted $0.32.  Full Article

Perceptive Advisors reports 6.8 pct passive stake in Dova Pharma
Tuesday, 1 Aug 2017 09:17am EDT 

Aug 1 (Reuters) - Perceptive Advisors Llc::Perceptive Advisors Llc reports a 6.8 pct passive stake in Dova Pharmaceuticals Inc <<>> as of July 5 - SEC filing.  Full Article

Dova Pharmaceuticals shares open at $19.25 in debut vs IPO price of $17/shr
Thursday, 29 Jun 2017 10:25am EDT 

June 29 (Reuters) - :Dova Pharmaceuticals Inc shares open at $19.25 in debut on the Nasdaq versus IPO price of $17.00.  Full Article